Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200172 | 0.88 | CCR5 (0.42) | KMT2ACYP2D6CCR5TACR1TACR2 | |
| SCHEMBL5201454 | 0.87 | SLC6A2 (0.49) | MEN1KMT2ACYP3A4CYP2D6TSHR | |
| SCHEMBL5200127 | 0.86 | CCR5 (0.44) | CYP3A4CYP2D6CCR5TACR1TACR2 | |
| SCHEMBL5199616 | 0.86 | CCR5 (0.42) | CCR5TACR1TACR2 | |
| SCHEMBL9029048 | 0.81 | TACR2 (0.42) | CYP3A4CYP2D6TSHRUSP2GLA | |
| SCHEMBL9026960 | 0.81 | TACR2 (0.42) | CYP3A4CYP2D6TSHRUSP2GLA | |
| SCHEMBL6952753 | 0.81 | KMT2A (0.43) | MEN1KMT2AUSP2TACR1CNR1 | |
| SCHEMBL3979446 | 0.79 | TACR1 (0.44) | CYP3A4CYP2D6CCR5TACR1TACR2 | |
| SCHEMBL3980158 | 0.79 | EPHX2 (0.42) | CCR5TACR1TACR2CNR1EPHX2 | |
| SCHEMBL9027646 | 0.79 | TACR2 (0.42) | MEN1KMT2ACCR5TACR1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150970-B1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2007-08-22 | — | — | EP | disclosed |
| US-6951940-B2 | Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-10-04 | — | — | US | disclosed |
| US-20040072840-A1 | Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | US | disclosed |
| US-6642233-B1 | Strong affinity and high selectivity for the human NK1 receptors of substance P. | SANOFI-SYNTHELABO (FR) | 2003-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072840-A1 | Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | TACR1, TACR2, KCNJ11 | MEN1 3715/4885KMT2A 2903/4885CYP3A4 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.